Download 16 - LWW.com

Supplementary Table 1. Summary of IBD consensus guideline recommendations for infectious disease
screening in patients before starting immunomodulatory therapy
Reference
D’Haens(16)
Turner(39)
Le Saux(12)
Veereman-Wauters(13)
Rahier(15)
Ruemmele(191)
Calvet(71)
Nordgaard-Lassen(192)
This clinical report
Tuberculosis (TB)-specific
Reference
D’Haens(16)
Turner(39)
Le Saux(12)
Veereman-Wauters(13)
Rahier(15)
Ruemmele(191)
Calvet(71)
Solovic(89)
Recommended before starting
Could be considered before starting
TB, HBV, HIV
TB
HBV, HCV,VZV
a
TB, VZV
TB, HBV
TB, HBV, HIV, VZVa
EBV, HCV
TB, HBVb
TB, HBV, HCV
TB , HBV, VZVa
TB, HBV, HIV, VZV
HCV (based on risk factor assessment)
screening
Year
TB screening suggestions
2010
TB screening per local guidelines
2011
TB testing (NOS), CXR
2012
Risk factors, TST, CXR, consider IGRA
2012
Risk factors, possible CXR
2013
Patient history, CXR, TST, IGRA
2014
CXR, TST and/or IGRA
2013
Two consecutive TST or CXR and IGRA
2010
Summary of all guidelines, TB screening per local
guidelines
Nordgaard-Lassen(192)
2012
Risk factors, CXR and IGRA (TST if IGRA cannot be done)
This clinical report
2015
Risk factors, TST and IGRA; if any positive CXR
TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatitis C virus, HIV, human immunodeficiency virus; VZV,
varicella zoster virus; EBV, Epstein Barr virus; NOS, not otherwise specified; TST, tuberculin skin test;
CXR, chest x-ray; IGRA, interferon-gamma release assay